Announced Sat, 1 Aug · 17:04 IST
SMS Pharma Q1FY27 results: Revenue up 6%, PAT up 8%, EBITDA margin at 20%
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹374.50
prior close
₹375.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.7-2.1-2.0-2.9-2.9-4.5+1.2+0.4-0.1-5.5-0.1——
Up moveDown movePending
AI summary
SMS Pharma Q1FY27 revenue grew 6% YoY to 207 crore, PAT up 8% to 20.20 crore. EBITDA held at 20% margin despite higher freight and wage costs. Gross margin improved 217bps to 36%. ARV segment surged 69%, anti-erectile dysfunction up 262%, while anti-diabetic fell 69%. Completed 4 of targeted 10 DMF/CEP filings. 280 crore capex 43% done. Board approved 50 crore loan to peptide subsidiary.
Likely market impact
Broad-based API growth with stable margins. Capex and peptide push support FY27 outlook. Watch anti-diabetic decline and freight costs.